NASDAQ:PCSA Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis → Charles Payne’s Gift to Stock Investors (From Unstoppable Prosperity) (Ad) Free PCSA Stock Alerts $2.02 -0.08 (-3.81%) (As of 10:04 AM ET) Add Compare Share Share Today's Range$1.98▼$2.1350-Day Range$1.52▼$2.9952-Week Range$1.40▼$18.00Volume97,271 shsAverage Volume2.22 million shsMarket Capitalization$5.78 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Processa Pharmaceuticals alerts: Email Address Processa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside281.0% Upside$8.00 Price TargetShort InterestBearish8.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 7 Articles This WeekInsider TradingAcquiring Shares$105,895 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.82) to ($1.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.51 out of 5 stars 3.3 Analyst's Opinion Consensus RatingProcessa Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageProcessa Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.28% of the float of Processa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverProcessa Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Processa Pharmaceuticals has recently increased by 429.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProcessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthProcessa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PCSA. Previous Next 3.0 News and Social Media Coverage News SentimentProcessa Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Processa Pharmaceuticals this week, compared to 1 article on an average week.Search Interest16 people have searched for PCSA on MarketBeat in the last 30 days. This is an increase of 220% compared to the previous 30 days.MarketBeat Follows7 people have added Processa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Processa Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $105,895.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.20% of the stock of Processa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.93% of the stock of Processa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Processa Pharmaceuticals are expected to grow in the coming year, from ($3.82) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Processa Pharmaceuticals is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Processa Pharmaceuticals is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProcessa Pharmaceuticals has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Processa Pharmaceuticals Stock (NASDAQ:PCSA)Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.Read More PCSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCSA Stock News HeadlinesApril 30, 2024 | globenewswire.comProcessa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical ResearchApril 29, 2024 | americanbankingnews.comProcessa Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($1.18) Per Share, HC Wainwright Forecasts (NASDAQ:PCSA)April 30, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 27, 2024 | americanbankingnews.comProcessa Pharmaceuticals (NASDAQ:PCSA) Now Covered by HC WainwrightApril 26, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Processa Pharmaceuticals (PCSA) with Buy RecommendationApril 11, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 1.09%April 11, 2024 | finance.yahoo.comProcessa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b TrialApril 7, 2024 | finance.yahoo.comInsider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40kApril 30, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” March 28, 2024 | nz.finance.yahoo.comEva Mendes says she had 'non-verbal agreement' with Ryan Gosling to be a stay-at-home momMarch 28, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comProcessa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual MeetingFebruary 24, 2024 | msn.comProcessa Pharmaceuticals (PCSA) Price Target Increased by 1900.00% to 81.60February 21, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 21, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 14, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 14, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 6, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleFebruary 6, 2024 | investing.comProcessa Pharmaceuticals Inc (PCSA)February 1, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Closing of $7.0 Million Public OfferingFebruary 1, 2024 | msn.comProcessa Pharmaceuticals Announces Offering Pricing DetailsJanuary 27, 2024 | marketwatch.comProcessa Pharmaceuticals Shares Drop 24% After Pricing OfferingJanuary 26, 2024 | msn.comProcessa Pharmaceuticals prices discounted stock and warrants offering to raise $7MJanuary 26, 2024 | msn.comWhat's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?January 26, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingJanuary 25, 2024 | marketwatch.comProcessa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer TreatmentJanuary 25, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 DosesSee More Headlines Receive PCSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/30/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PCSA CUSIPN/A CIK1533743 Webwww.processapharmaceuticals.com Phone(443) 776-3133Fax443-288-4420Employees13Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+281.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($7.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-141.42% Return on Assets-122.25% Debt Debt-to-Equity RatioN/A Current Ratio7.70 Quick Ratio7.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.05 per share Price / Book0.52Miscellaneous Outstanding Shares2,860,000Free Float2,222,000Market Cap$6.01 million OptionableNot Optionable Beta0.53 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. George K. Ng Esq. (Age 50)J.D., Chief Executive Officer Comp: $400.27kDr. David Young Ph.D. (Age 71)Pharm.D., Co-Founder, President of Research and Development & Director Comp: $160.2kDr. Sian E. Bigora Ph.D. (Age 64)Pharm.D., Co-Founder and Chief Development & Regulatory Officer Comp: $184.87kMr. James H. Stanker (Age 66)Chief Financial Officer Comp: $160.2kMr. Patrick Lin (Age 59)Co-Founder, Chief Business & Strategy Officer Comp: $117.15kMs. Wendy J. Guy (Age 60)Co-Founder, Chief Administrative Officer & Corporate Secretary Comp: $94.19kMore ExecutivesKey CompetitorsLongeveronNASDAQ:LGVNChina PharmaNYSE:CPHIExicureNASDAQ:XCURSeelos TherapeuticsNASDAQ:SEELPetros PharmaceuticalsNASDAQ:PTPIView All CompetitorsInsiders & InstitutionsDavid YoungBought 21,000 shares on 2/7/2024Total: $51,450.00 ($2.45/share)Spinnaker TrustBought 76,865 shares on 2/2/2024Ownership: 6.249%Patrick LinBought 2,500 shares on 1/31/2024Total: $5,925.00 ($2.37/share)Justin W YorkeBought 8,000 shares on 1/30/2024Total: $21,520.00 ($2.69/share)George K NgBought 10,000 shares on 1/30/2024Total: $27,000.00 ($2.70/share)View All Insider TransactionsView All Institutional Transactions PCSA Stock Analysis - Frequently Asked Questions Should I buy or sell Processa Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PCSA shares. View PCSA analyst ratings or view top-rated stocks. What is Processa Pharmaceuticals' stock price target for 2024? 3 Wall Street analysts have issued 12-month target prices for Processa Pharmaceuticals' shares. Their PCSA share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 281.0% from the stock's current price. View analysts price targets for PCSA or view top-rated stocks among Wall Street analysts. How have PCSA shares performed in 2024? Processa Pharmaceuticals' stock was trading at $6.6920 at the start of the year. Since then, PCSA shares have decreased by 68.6% and is now trading at $2.10. View the best growth stocks for 2024 here. Are investors shorting Processa Pharmaceuticals? Processa Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 189,600 shares, an increase of 429.6% from the March 31st total of 35,800 shares. Based on an average daily volume of 1,560,000 shares, the short-interest ratio is currently 0.1 days. Currently, 8.3% of the company's shares are sold short. View Processa Pharmaceuticals' Short Interest. When is Processa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PCSA earnings forecast. How were Processa Pharmaceuticals' earnings last quarter? Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) released its quarterly earnings data on Friday, March, 29th. The company reported ($0.24) earnings per share for the quarter. When did Processa Pharmaceuticals' stock split? Processa Pharmaceuticals shares reverse split on Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Processa Pharmaceuticals? Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PCSA) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
